Articles

Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Memorial Sloan Kettering Cancer Center, New York, NY
Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm
Center of Oncology of the Lublin Region, St. Jana z Dukli, Lublin
Department of Hematology and Cancer Prevention, School of Public Health in Bytom, Medical University of Silesia in Katowice, Katowice
S. P. Botkin City Clinical Hospital, Moscow, Russian Federation
1st Medical Department – Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
Clinica Medica São Germano, São Paulo
Kiev Center for Bone Marrow Transplantation, Kiev
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB
Department of Internal Medicine, Falun General Hospital, Falun
Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona
Hematology Department, University Hospital Hôtel-Dieu, Nantes
Division of Genetics and Epidemiology, The Institute of Cancer Research and The Royal Marsden Hospital, London
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya
Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Aviv University, Aviv
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica, e Sperimentale, Università degli Studi, Bologna
Department of Hematology, Hôpital Haut Lévêque, Pessac
Dalhousie University and Queen Elizabeth II Health Science Centre, Halifax, NS
Institute of Hematology, Catholic University, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome
Janssen Research and Development, LLC, Spring House, PA
Janssen Research and Development, LLC, Spring House, PA
Janssen Research and Development, LLC, Spring House, PA
Janssen Research and Development, LLC, Spring House, PA
Janssen Research and Development, LLC, Raritan, NJ
Janssen Research and Development, LLC, Spring House, PA
Janssen Research and Development, LLC, Spring House, PA
University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca
Haematologica Early view Mar 31, 2022 https://doi.org/10.3324/haematol.2021.279459